Polidocanol - BTG

Drug Profile

Polidocanol - BTG

Alternative Names: PEM; Polidocanol Endovenous Microfoam; Polidocanol injectable foam; Varisolve PEM; Varisolve®; Varithena

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator BTG
  • Developer BTG; BTG International
  • Class Polyethylene glycols; Sclerosants; Vascular disorder therapies
  • Mechanism of Action Endothelial cell modulators; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Varicose veins

Highest Development Phases

  • Marketed Varicose veins

Most Recent Events

  • 06 Jul 2016 The FDA approves a 30 day post-activation shelf life of polidocanol in USA
  • 06 Aug 2015 Registered for Varicose veins in Canada (IV)
  • 11 Aug 2014 Launched for Varicose veins in USA (IV) - First Global Launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top